In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Immunocore Holdings plc ADR (NASDAQ: IMCR) closed the day trading at $32.85 up 0.31% from the previous closing price of $32.75. In other words, the price has increased by $0.31 from its previous closing price. On the day, 0.51 million shares were traded. IMCR stock price reached its highest trading level at $33.682 during the session, while it also had its lowest trading level at $32.5.
Ratios:
For a better understanding of IMCR, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 579.70. For the most recent quarter (mrq), Quick Ratio is recorded 5.97 and its Current Ratio is at 6.00. In the meantime, Its Debt-to-Equity ratio is 1.10 whereas as Long-Term Debt/Eq ratio is at 1.09.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 31, 2025, initiated with a Overweight rating and assigned the stock a target price of $60.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 04 ’25 when Berman David M sold 31,341 shares for $40.26 per share. The transaction valued at 1,261,789 led to the insider holds 0 shares of the business.
Berman David M sold 572 shares of IMCR for $22,960 on Dec 05 ’25. The HEAD OF R&D now owns 0 shares after completing the transaction at $40.14 per share. On Nov 26 ’25, another insider, Berman David M, who serves as the HEAD OF R&D of the company, sold 69,404 shares for $40.12 each. As a result, the insider received 2,784,488 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMCR now has a Market Capitalization of 1659924224 and an Enterprise Value of 1203433216. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.37 while its Price-to-Book (P/B) ratio in mrq is 4.20. Its current Enterprise Value per Revenue stands at 3.17 whereas that against EBITDA is -51.286.
Stock Price History:
The Beta on a monthly basis for IMCR is 0.78, which has changed by 0.08336091 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, IMCR has reached a high of $40.71, while it has fallen to a 52-week low of $23.15. The 50-Day Moving Average of the stock is -8.12%, while the 200-Day Moving Average is calculated to be -1.45%.
Shares Statistics:
Over the past 3-months, IMCR traded about 307.72K shares per day on average, while over the past 10 days, IMCR traded about 317920 shares per day. A total of 50.47M shares are outstanding, with a floating share count of 50.08M. Insiders hold about 0.76% of the company’s shares, while institutions hold 97.66% stake in the company. Shares short for IMCR as of 1765756800 were 9052969 with a Short Ratio of 29.42, compared to 1763078400 on 8767994. Therefore, it implies a Short% of Shares Outstanding of 9052969 and a Short% of Float of 24.66.
Earnings Estimates
The performance of Immunocore Holdings plc ADR (IMCR) in the stock market is under the watchful eye of 11.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.11, with high estimates of $0.02 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.11 and -$0.5 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.84, with 14.0 analysts recommending between $0.45 and -$2.28.
Revenue Estimates
14 analysts predict $107.82M in revenue. The current quarter. It ranges from a high estimate of $112.97M to a low estimate of $102.7M. As of. The current estimate, Immunocore Holdings plc ADR’s year-ago sales were $84.05MFor the next quarter, 14 analysts are estimating revenue of $109.6M. There is a high estimate of $115.8M for the next quarter, whereas the lowest estimate is $101M.
A total of 16 analysts have provided revenue estimates for IMCR’s current fiscal year. The highest revenue estimate was $408.51M, while the lowest revenue estimate was $398.3M, resulting in an average revenue estimate of $403.14M. In the same quarter a year ago, actual revenue was $310.2MBased on 16 analysts’ estimates, the company’s revenue will be $445.78M in the next fiscal year. The high estimate is $489M and the low estimate is $417.4M.
